These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19038872)

  • 1. Controlling prescription drug costs: regulation and the role of interest groups in Medicare and the Veterans Health Administration.
    Frakt AB; Pizer SD; Hendricks AM
    J Health Polit Policy Law; 2008 Dec; 33(6):1079-106. PubMed ID: 19038872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating private sector values for VA health care: an overview.
    Nugent G; Hendricks A
    Med Care; 2003 Jun; 41(6 Suppl):II2-10. PubMed ID: 12773822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Out-of-pocket pharmacy expenditures for veterans under medicare part D.
    Rupper RW; Bair BD; Sauer BC; Nebeker JR; Shinogle J; Samore M
    Med Care; 2007 Oct; 45(10 Supl 2):S77-80. PubMed ID: 17909387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should Medicare adopt the Veterans Health Administration formulary?
    Frakt AB; Pizer SD; Feldman R
    Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VA payment for non-VA public or private hospital care and non-VA physician services that are associated with either outpatient or inpatient care. Department of Veterans Affairs. Final rule.
    Fed Regist; 2000 Nov; 65(216):66636-7. PubMed ID: 11503698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value for taxpayers' dollars: what VA care would cost at medicare prices.
    Nugent GN; Hendricks A; Nugent L; Render ML
    Med Care Res Rev; 2004 Dec; 61(4):495-508. PubMed ID: 15536211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 8. When VA patients have non-VA hospitalizations, who pays for what services, and what are the research implications? A New York case study.
    West AN; Weeks WB; Wright SM; Wallace AE; Fisher ES
    Med Care; 2008 Aug; 46(8):872-7. PubMed ID: 18665067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.
    Seay M; Varma P
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription drug spending: contribution to health care spending and cost containment strategies.
    Rivers PA; Hall NG; Frimpong J
    J Health Care Finance; 2006; 32(3):8-19. PubMed ID: 18975728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare should bargain for lower drug prices, study says.
    Med Health; 2005 Oct; 59(36):1, 3, 7. PubMed ID: 16240494
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical and policy implications of using different rural-urban classification systems: a case study of inpatient service utilization among Veterans Administration users.
    Berke EM; West AN; Wallace AE; Weeks WB
    J Rural Health; 2009; 25(3):259-66. PubMed ID: 19566611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VA-Medicare dual beneficiaries' enrollment in Medicare HMOs: access to VA, availability of HMOs, and favorable selection.
    Shen Y; Hendricks A; Li D; Gardner J; Kazis L
    Med Care Res Rev; 2005 Aug; 62(4):479-95. PubMed ID: 16049135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods to estimate and compare VA expenditures for assistive devices to Medicare payments.
    Render ML; Taylor P; Plunkett J; Nugent GN
    Med Care; 2003 Jun; 41(6 Suppl):II70-9. PubMed ID: 12773829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should drug prices be negotiated under part D of Medicare? And if so, how?
    Frank RG; Newhouse JP
    Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who pays when VA users are hospitalized in the private sector? Evidence from three data sources.
    West AN; Weeks WB
    Med Care; 2007 Oct; 45(10):1003-7. PubMed ID: 17890999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 18. How can states provide affordable pharmaceuticals to the underserved?
    Zara J
    J Health Care Poor Underserved; 2006 Nov; 17(4):808-20. PubMed ID: 17242532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should healthy Medicare beneficiaries postpone enrollment in Medicare Part D?
    Atherly A; Dowd B
    Health Econ; 2009 Aug; 18(8):921-31. PubMed ID: 18972327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Looking inside the nation's medicine cabinet: trends in outpatient drug spending by Medicare beneficiaries, 1997 and 2001.
    Moeller JF; Miller GE; Banthin JS
    Health Aff (Millwood); 2004; 23(5):217-25. PubMed ID: 15371388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.